Bristol takes its bispecific conjugate into lung cancer
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
More delays for Regeneron
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
FDA red and green lights: July 2025
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
Bristol pulls ahead of Amgen
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
Revolution mortgages royalties for more cash
“We need all the capital we can get our hands on," the company states.
Better late than never for Datroway in lung cancer
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
ArriVent goes Further into PACC mutations
The group is aiming for accelerated approval with the upcoming Alpacca trial.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Pfizer bets big on a bispecific
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
